Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment.

JSON

Antimycobacterial Susceptibility Testing Group

Eur. Respir. J. 59 (4) - [2022-04-00; online 2022-04-14]

Inappropriately high breakpoints have resulted in systematic false-susceptible AST results to anti-TB drugs. MIC, PK/PD and clinical outcome data should be combined when setting breakpoints to minimise the emergence and spread of antimicrobial resistance. https://bit.ly/3i43wb6

PubMed 35422426

DOI 10.1183/13993003.00166-2022

Crossref 10.1183/13993003.00166-2022

pmc: PMC9059840
pii: 59/4/2200166